Belt and Road Summit 2025- Deal-making

10–16 Sept 2025 | China (Hong Kong)

Daisy Tan

Business Development Officer

InnoHK Centre for Translational Stem Cell Biology

Hong Kong, China (Hong Kong)

13 profile visitsProject Owner

My organisation

InnoHK Centre for Translational Stem Cell Biology (InnoHK CTSCB) leads global innovation in regenerative medicine, driving next-generation stem cell technology to achieve real-world impact. Through partnerships with the University of Hong Kong and the University of Cambridge and supported by the InnoHK initiative of the Innovation and Technology Commission, we transform pioneering discoveries into innovative applications and commercial successes.   Our patented Expanded Potential Stem Cell (EPSC) technology uniquely enables the generation of every human cell type, including embryonic and extra-embryonic lineages. This breakthrough technology accelerates the development of intelligent drug screening, precision medicine, and cell-based therapies, ultimately improving patient outcomes and enhancing quality of life worldwide.  Driven by our vision for healthy longevity and a spirit of collaboration, InnoHK CTSCB brings together leading experts from around the world, fostering a vibrant culture of innovation. We are dedicated to translating cutting-edge research into life-changing medicine, building a healthier future for all.
Read more

About me

Social media

Marketplace (4)

  • Project

    Estelle Biovita

    Estelle Biovita combines human-derived stem cell​ secretions with nanotechnology​ for intelligent dermal health.

    • No
    • None
    • Bio-Tech
    • Technology
    • Joint Venture
    • R&D Cooperation
    • Project Planning
    • Health Technology
    • Financial Services
    • 500,000 USD or Below
    • Open for Negotiation
    • Open for negotiation
    • Professional Services
    • 1,000,001 to 2,500,000 USD
    • Public-Private Partnership Project
    Author

    Daisy Tan

    Business Development Officer at InnoHK Centre for Translational Stem Cell Biology

    Hong Kong, China (Hong Kong)

  • Project

    Genome Technology

    Rapid Generation Of Gene-Edited Mice for Accelerated Research

    • No
    • Bio-Tech
    • Operations
    • Technology
    • Private Project
    • Seed & Pre-Series
    • Medical Technology
    • Financial Services
    • Open for Negotiation
    • Open for negotiation
    • Professional Services
    • 500,001 to 1,000,000 USD
    • 1,000,001 to 2,500,000 USD
    Author

    Daisy Tan

    Business Development Officer at InnoHK Centre for Translational Stem Cell Biology

    Hong Kong, China (Hong Kong)

  • Project

    Trophy Life Technology

    Your Partner in Next-Gen Antiviral Innovation

    • No
    • Bio-Tech
    • Technology
    • Joint Venture
    • R&D Cooperation
    • Project Planning
    • Health Technology
    • Seed & Pre-Series
    • Financial Services
    • 500,000 USD or Below
    • Open for Negotiation
    • Open for negotiation
    • Professional Services
    • Requisition of Service
    • 1,000,001 to 2,500,000 USD
    • Public-Private Partnership Project
    Author

    Daisy Tan

    Business Development Officer at InnoHK Centre for Translational Stem Cell Biology

    Hong Kong, China (Hong Kong)

  • Project

    Synhealer

    AB-CAR-M Therapy– Enhanced Living Drug for Solid Tumors

    • No
    • None
    • Bio-Tech
    • Technology
    • Joint Venture
    • R&D Cooperation
    • Project Planning
    • Health Technology
    • Financial Services
    • Open for Negotiation
    • Open for negotiation
    • Professional Services
    • 1,000,001 to 2,500,000 USD
    • 2,500,001 to 5,000,000 USD
    • Public-Private Partnership Project
    Author

    Daisy Tan

    Business Development Officer at InnoHK Centre for Translational Stem Cell Biology

    Hong Kong, China (Hong Kong)